Establishment Labs Q3 2026 Earnings: Revenue Rises 33.9% as Free Cash Flow Turns Positive

Establishment Labs (NASDAQ: ESTA) reported Q3 2026 revenue of $72.0 million, up 33.9% from $53.8 million a year earlier, while its GAAP diluted loss per share narrowed to $0.35 from $0.38. The main developments were 119% U.S. revenue growth, higher adjusted EBITDA, and the company’s first quarter of positive operating and free cash flow, although interest expense and lower-margin distributor sales continued to affect GAAP profitability.

Core Financial Results

Revenue growth translated into better operating leverage. GAAP operating expenses increased to $52.3 million from $41.7 million, but adjusted operating expenses declined to 68.8% of revenue from 77.6%, an improvement of 880 basis points.

GAAP gross margin fell by 100 basis points, partly because of $1.3 million in restructuring-related inventory charges. Excluding those charges, adjusted gross margin rose by 70 basis points as the higher-margin U.S. business and minimally invasive platform expanded.

The relatively modest improvement in net loss compared with the larger gain in adjusted EBITDA reflects expenses outside the adjusted operating measure, including $6.8 million of quarterly interest expense and litigation and restructuring-related items.

Business and Geographic Performance

The U.S. was the main growth engine, while outside-the-U.S. revenue remained the larger business by dollars but expanded more slowly. Minimally invasive products also grew faster than the company as a whole.

Establishment Labs expanded its U.S. commercial footprint to more than 2,100 accounts and trained more than 400 plastic surgeons on Preservé. The FDA also approved additional smaller Motiva implant sizes, while the company announced larger implant sizes for its minimally invasive platform.

Outside the U.S., stronger-than-anticipated distributor sales contributed additional revenue and gross profit dollars. However, those sales carry lower margins, creating a trade-off between faster near-term revenue and consolidated gross margin.

The FDA review of Motiva for breast reconstruction was progressing in line with the company’s expectations. Establishment Labs also signed a new supply agreement with NuSil to support long-term manufacturing capacity.

Positive Quarterly Cash Flow Marks Progress, but Debt Costs Still Matter

The quarter’s cash flow milestone did not yet make year-to-date cash generation positive. For the first nine months of 2026, operating cash flow remained negative at $13.2 million, while investing activities used another $8.2 million.

Financing activities provided $22.5 million during the nine-month period, helping cash and cash equivalents remain nearly unchanged at $75.8 million compared with $75.6 million at the end of 2025. At the same time, the note payable increased to $267.8 million from $247.5 million.

Debt costs remain an important distinction between operating progress and bottom-line profitability. The company reduced its quarterly operating loss to $2.6 million, but reported a $10.7 million net loss after recording $6.8 million of interest expense, up from $6.2 million a year earlier.

Financial Guidance

Establishment Labs raised its full-year 2026 revenue outlook following the third-quarter performance. The adjusted operating expense range was unchanged, while the gross margin outlook incorporates a larger mix of lower-margin outside-the-U.S. distributor sales.

Management separately said it expects fiscal 2027 to deliver 25% growth and positive cash flow, with minimally invasive products and breast reconstruction identified as important opportunities. The company did not specify the revenue or earnings basis of the stated 25% growth expectation.

Recent Insider Transactions

The supplied six-month insider summary showed more reported sales than purchases. Nine of the 10 latest individual entries were director stock awards rather than market purchases; the remaining entry was an indirect sale by a greater-than-10% beneficial owner.

These disclosures describe transaction activity and do not, by themselves, establish insiders’ views of the company’s prospects.

Risks Investors Should Monitor

• Sales mix pressure: Faster outside-the-U.S. distributor sales add revenue and gross profit dollars but carry lower margins, which could limit consolidated gross margin expansion.
• Cash flow durability: Q3 was the first positive operating and free cash flow quarter, but nine-month operating cash flow remained negative. Sustaining quarterly cash generation is therefore a key follow-up measure.
• Debt and interest expense: The $267.8 million note payable and $6.8 million of quarterly interest expense continue to create a substantial gap between operating performance and GAAP net income.
• Commercial and regulatory execution: Continued growth depends partly on expanding the U.S. account base, increasing minimally invasive adoption, and advancing Motiva’s FDA review for breast reconstruction.

Summary

Establishment Labs’ Q3 2026 results showed that rapid U.S. and minimally invasive growth is beginning to produce operating leverage and positive quarterly cash flow. Adjusted EBITDA improved substantially and full-year revenue guidance increased, but lower-margin distributor sales, negative year-to-date operating cash flow, and a significant interest burden remain the main issues to monitor as the company works toward sustained cash generation.